Citigroup Issues Positive Forecast for AstraZeneca (LON:AZN) Stock Price

AstraZeneca (LON:AZN) had its target price lifted by stock analysts at Citigroup from £175 to £178 in a research report issued to clients and investors on Tuesday,Digital Look reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup’s price objective indicates a potential upside of 39.50% from the stock’s current price.

AZN has been the subject of several other research reports. Berenberg Bank reissued a “buy” rating and issued a £160 price target on shares of AstraZeneca in a report on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research report on Friday, June 26th. Finally, Jefferies Financial Group reissued a “buy” rating and set a £180 target price on shares of AstraZeneca in a research report on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus target price of £153.

AstraZeneca Stock Down 1.0%

AstraZeneca stock opened at £127.60 on Tuesday. AstraZeneca has a twelve month low of £107.44 and a twelve month high of £157.32. The business has a fifty day moving average of £134.89 and a two-hundred day moving average of £140.60. The firm has a market cap of £197.89 billion, a P/E ratio of 19.22, a P/E/G ratio of 0.86 and a beta of 0.23. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.